LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Home・Aandelen Lijst・REVOLUTION Medicines Inc

REVOLUTION Medicines Inc

Gesloten

SectorGezondheidszorg

79.69 1.98

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

78.94

Max

79.79

Belangrijke statistieken
By Trading Economics
Inkomsten	-57M -305M
Winstmarge	-74.379
Werknemers	809
EBITDA	-41M -302M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+0.39% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	3.6B 15B
Vorige openingsprijs	77.71
Vorige sluitingsprijs	79.69

Nieuwssentiment

By Acuity

58%

42%

313 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

40.67 / 41.96 Steun & Weerstand

REVOLUTION Medicines Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 okt 2025, 18:13 UTC

Belangrijke Marktbewegers

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

Peer Vergelijking

Prijswijziging

REVOLUTION Medicines Inc Prognose

Koersdoel

By TipRanks

0.39% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 79.95 USD 0.39%

Hoogste 104 USD

Laagste 67 USD

Gebaseerd op 20 Wall Street-analisten die 12-maands prijsdoelen bieden voor REVOLUTION Medicines Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

20 ratings

Buy

Hold

Sell

Gebaseerd op 20 analisten die aandelenratings hebben gegeven aan REVOLUTION Medicines Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

40.67 / 41.96Steun & Weerstand

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

313 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.